Journal: Current Therapeutic Research, Clinical and Experimental

Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

doi: 10.1016/j.curtheres.2026.100826

Figure Lengend Snippet: Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

Article Snippet: Spontaneous post-marketing ADR reports for Kedrion 5% IVIg (January 1997–May 2025) were descriptively analyzed using the Kedrion Pharmacovigilance Database.

Techniques:

Journal: Current Therapeutic Research, Clinical and Experimental

Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

doi: 10.1016/j.curtheres.2026.100826

Figure Lengend Snippet: Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

Article Snippet: Spontaneous post-marketing ADR reports for Kedrion 5% IVIg (January 1997–May 2025) were descriptively analyzed using the Kedrion Pharmacovigilance Database.

Techniques:

Journal: Current Therapeutic Research, Clinical and Experimental

Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

doi: 10.1016/j.curtheres.2026.100826

Figure Lengend Snippet: Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

Article Snippet: Spontaneous post-marketing ADR reports for Kedrion 5% IVIg (January 1997–May 2025) were descriptively analyzed using the Kedrion Pharmacovigilance Database.

Techniques:

Journal: Current Therapeutic Research, Clinical and Experimental

Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

doi: 10.1016/j.curtheres.2026.100826

Figure Lengend Snippet: Cumulative reporting of most frequent ADRs with this Kedrion 5% IVIg by frequency and seriousness (1 January 1997–31 May 20254).

Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

Techniques:

Journal: Current Therapeutic Research, Clinical and Experimental

Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

doi: 10.1016/j.curtheres.2026.100826

Figure Lengend Snippet: Distribution of ADRs reported with this Kedrion 5% IVIg by age group and sex.

Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

Techniques:

Journal: Current Therapeutic Research, Clinical and Experimental

Article Title: Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

doi: 10.1016/j.curtheres.2026.100826

Figure Lengend Snippet: Distribution of serious vs non-serious ADRs reported with this Kedrion 5% IVIg by age group and sex.

Article Snippet: Of note, 1,758 ADRs were associated with individual cases in which the reported brand name corresponded to a Kedrion-manufactured 5% IVIg product included in this analysis.

Techniques: